SUMMIT THERAPEUTICS INC (SMMT) Stock Analyst Earnings Estimates
NASDAQ:SMMT - Nasdaq - US86627T1088 - Common Stock - Currency: USD
Full estimates are only available for subscribed users, you can see which data is available below.
Subscribed users also see more surprise data, now it is restricted to 4 quarters.
Examples of complete estimate data are available for MSFT and AAPL.
Registered users have access to more data. Please register or login for additional estimates and surprises .
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 860K -98.49% | 1.81M 110.47% | 710K -60.77% | N/A -100.00% | 693.6K | 190M 27,293.31% | 1.041B 447.89% | 2.467B 136.98% | 4.089B 65.75% | 5.66B 38.42% | 7.283B 28.67% | |||
| EBITDA YoY % growth | -50.78M -488.82% | -84.84M -67.07% | -62.36M 26.50% | N/A -41.98% | -224.001M -153.00% | -277.746M -23.99% | -312.022M -12.34% | N/A | N/A | N/A | N/A | N/A | N/A | |
| EBIT YoY % growth | -52.33M -563.51% | -86.19M -64.70% | -63.62M 26.19% | N/A -39.48% | -226.217M -154.94% | -304.147M -34.45% | -442.701M -45.55% | -462.252M -4.42% | 256.7M 155.53% | 2B 679.12% | 3.601B 80.05% | 5.363B 48.93% | 6.524B 21.65% | |
| Operating Margin | -6,084.88% | -4,761.88% | -8,960.56% | N/A | N/A | N/A | -63,826.56% | -243.29% | 24.66% | 81.07% | 88.07% | 94.75% | 89.58% | |
| EPS YoY % growth | -3.39 | N/A | N/A | N/A | -0.30 -100.99% | -0.42 -39.10% | -0.58 -38.83% | -0.55 4.70% | 0.42 175.92% | 2.05 385.47% | 3.86 88.94% | 7.29 88.56% | 9.04 24.11% |
All data in USD
| Q4 / 24 | Q1 / 25 | Q2 / 25 | Q3 / 25 | Q4 / 25 | |
|---|---|---|---|---|---|
| EPS Q2Q % growth | -0.08 -107.29% | -0.08 -36.00% | -0.09 -2.00% | -0.10 -27.50% | -0.12 -43.52% |
| Revenue Q2Q % growth | -100.00% | ||||
| EBITDA Q2Q % growth | -60.368M -67.63% | N/A | N/A | N/A | N/A |
| EBIT Q2Q % growth | -63.156M -74.42% | -60.486M -48.25% | -62.858M -33.97% | -65.28M -11.82% | -69.87M -10.63% |
All data in USD
| Period | Reported | Estimate | Difference | Surprise |
|---|---|---|---|---|
| Q3 2024 Q2Q % growth | -0.08 -166.67% | -0.07 | -0.01 | -17.64% |
| Q2 2024 Q2Q % growth | -0.09 -350.00% | -0.06 | -0.03 | -42.31% |
| Q1 2024 Q2Q % growth | -0.06 | -0.06 | 0.00 | 1.96% |
| Q4 2023 Q2Q % growth | -0.04 42.86% | % | ||
| Q3 2023 Q2Q % growth | -0.03 78.57% | % | ||
| Q3 2022 Q2Q % growth | -0.14 86.00% | % | ||
| Q3 2021 Q2Q % growth | -1.00 19.35% | -0.30 | -0.70 | -238.07% |
| Q2 2021 Q2Q % growth | 99.77% | 0.00 | % | |
| Q1 2021 Q2Q % growth | -1.05 -950.00% | 0.00 | -1.05 | -39,799.68% |
| Q4 2020 Q2Q % growth | -0.90 | 0.00 | -0.90 | -40,006.95% |
| Q3 2020 Q2Q % growth | -1.24 | -0.01 | -1.23 | -10,852.13% |
| Q2 2020 Q2Q % growth | -1.15 | -0.02 | -1.13 | -5,537.25% |
| Q1 2020 Q2Q % growth | -0.10 | -0.02 | -0.08 | -390.20% |
| Period | Reported | Estimate | Difference | Surprise |
|---|---|---|---|---|
| Q3 2024 Q2Q % growth | -100.00% | % | ||
| Q3 2023 Q2Q % growth | 270K 22.73% | % | ||
| Q2 2023 Q2Q % growth | -100.00% | % | ||
| Q1 2023 Q2Q % growth | -100.00% | % | ||
| Q4 2022 Q2Q % growth | -100.00% | % | ||
| Q3 2022 Q2Q % growth | 220K -83.21% | % | ||
| Q2 2022 Q2Q % growth | 240K 300.00% | % | ||
| Q1 2022 Q2Q % growth | 250K 31.58% | % | ||
| Q4 2021 Q2Q % growth | 250K 31.58% | % | ||
| Q3 2021 Q2Q % growth | 1.31M 627.78% | 1.31M | % | |
| Q2 2021 Q2Q % growth | 60K -64.71% | 4.518M | -4.458M | -98.67% |
| Q1 2021 Q2Q % growth | 190K -40.63% | 4.495M | -4.305M | -95.77% |
| Q4 2020 Q2Q % growth | 190K | 3.913M | -3.723M | -95.14% |
| Q3 2020 Q2Q % growth | 180K 20.00% | 4.041M | -3.861M | -95.55% |
| Q2 2020 Q2Q % growth | 170K 6.25% | 4.59M | -4.42M | -96.30% |
| Q1 2020 Q2Q % growth | 320K -34.69% | 5.171M | -4.851M | -93.81% |
| Next Q (1 month) | Next Q (3 month) | Next Year (1 month) | Next Year (3 month) | |
|---|---|---|---|---|
| EPS | -5.23% | -5.23% | -1.4% | 2.21% |
| Revenue | N/A | N/A | N/A | N/A |